Race Oncology highlights impressive bisantrene clinical data
November 07, 2023 at 12:16 pm EST
Share
(via NewsDirect)
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith discusses with Proactive impressive Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in relapsed or refractory acute myeloid leukaemia patients. Administered over four days, the drug combination induced a clinical response in 40% of evaluable patients with five patients receiving a potentially curative stem cell transplant.
“To see such meaningful clinical responses in a group that would typically be receiving palliative care is striking," said Smith.
"It is also encouraging that the safety profile was manageable, even for this advanced patient population.
"These are highly positive outcomes in a heavily pretreated patient population.”
Contact Details
Proactive Investors
Gregg Castano
+1 203-762-5649
gregg.castano@newsdirect.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.